ALSO NOTED: MedImmune bid a 'go'; Jazz gains $108M in IPO;and much more...

> AstraZeneca says its tender offer for MedImmune was a success, allowing its acquisition to proceed. Report [1]

> Jazz Pharmaceuticals raised $108 million in its IPO as it sold shares well under its forecasted range. Release [2]

> Accu-Break Pharmaceuticals has raised a $5.65 million in a new round of venture capital led by S.A.C. Capital Associates and funds managed by Pequot Capital Management. Report [3]

> The FDA has approved Novo Nordisk's Norditropin, a growth hormone, for children of short stature who suffer from Noonan syndrome. Report [4]

> Indigo Pharmaceuticals has signed a license agreement for INDI-702 (previously NM-702; current development code in Japan: NT-702) with Tokyo-based Nissan Chemical Industries and Taisho Pharmaceutical. Nissan Chemical and Taisho have been jointly developing INDI-702 for arteriosclerosis obliterans. Release [5]

> Shares of Amicus Therapeutics slipped 3.8 percent during their opening day on Nasdaq. Report [6]

> AstraZeneca today announced a ruling by the US District Court for the Southern District of New York that found two Prilosec formulation patents valid and infringed by Impax Laboratories and Apotex Corp. Release [7] 

> Nventa Biopharmaceuticals has consolidated its offices in its San Diego facility, closing operations in Canada. Release [8]

> VGX Pharmaceuticals has formed a wholly owned subsidiary, VGX Animal Health. Release [9]

And Finally…The recent case of an Atlanta man who traveled around the world with a case of extremely drug-resistant TB is highlighting fears that the disease could kill millions if it breaks out into the general population. Report [10]